Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mHSPC”

75 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 75 results

Large-scale testing (Phase 3)Looking for participantsNCT05956639
What this trial is testing

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University 100
Large-scale testing (Phase 3)Looking for participantsNCT06496581
What this trial is testing

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Who this might be right for
Prostate Cancer Metastatic
UNICANCER 500
Not applicableLooking for participantsNCT07395804
What this trial is testing

How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07645326
What this trial is testing

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Georgetown University 108
Not applicableLooking for participantsNCT06661122
What this trial is testing

Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer 100
Not applicableLooking for participantsNCT07223372
What this trial is testing

An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia

Who this might be right for
Metastatic Hormonesensitive Prostate Cancer (mHSPC)
Bayer 1,000
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Large-scale testing (Phase 3)Looking for participantsNCT07241416
What this trial is testing

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 206
Testing effectiveness (Phase 2)Active Not RecruitingNCT06991556
What this trial is testing

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Novartis Pharmaceuticals 168
Not applicableActive Not RecruitingNCT06865547
What this trial is testing

ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Yonghong Li 94
Not applicableNot Yet RecruitingNCT07112612
What this trial is testing

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
MRDProstate CancermHSPC
Anhui Medical University 50
Not applicableNot Yet RecruitingNCT07644754
What this trial is testing

Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases

Who this might be right for
Prostate CancerProstate Cancer Metastatic DiseaseProstate Cancer Metastatic to Bone
University Hospital Tuebingen 27
Not applicableNot Yet RecruitingNCT07804030
What this trial is testing

AI-Assisted Patient Support in mHSPC

Who this might be right for
Metastatic Prostate Cancer
Fudan University 160
Large-scale testing (Phase 3)Active Not RecruitingNCT04076059
What this trial is testing

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd. 180
Testing effectiveness (Phase 2)Looking for participantsNCT07190300
What this trial is testing

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals 181
Not applicableNot Yet RecruitingNCT07806591
What this trial is testing

Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Bayer 50
Testing effectiveness (Phase 2)Study completedNCT03899467
What this trial is testing

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc, 61
Large-scale testing (Phase 3)UnknownNCT05627752
What this trial is testing

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Who this might be right for
Prostate CancerCastrate Resistant Prostate Cancer
Zhongnan Hospital 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04126070
What this trial is testing

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Who this might be right for
Hormone Sensitive Prostate CancerProstate AdenocarcinomaMetastasis Prostate Adenocarcinoma
Xiao X. Wei, MD 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07268794
What this trial is testing

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fudan University 112
Next Page